Financials
Financial year 2025
Gross margin
€ 175,986
▲ 2051% vs 2024
Profit
Growing€ 127,985
▲ 592% vs 2024
Debts
Low€ 39,329
▼ 19% vs 2024
QUIDDITAS from Liège, company number BE0794472362, closed financial year 2025 with a result of € 127,985 after tax. For that financial year QUIDDITAS recorded a gross margin of € 175,986 and equity of € 1.1 million. Compared with financial year 2024, the result moved from € -26,028 to € 127,985. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
What happened at QUIDDITAS?
What happened at QUIDDITAS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 127,985. Source: NBB ↗
- Aurore PRUNEVIEILLE became a director. NBB
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 17,663 loss in 2023 to € 127,985 profit in 2025.
Paid € 172 in corporate taxes since 2023.
Best year ever: 2025, with € 127,985 profit.
On average € 176,000 of value added per employee in 2025.
A new publication or filing at QUIDDITAS? We notify you, reason included.
Follow QUIDDITASNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind QUIDDITAS are Aurore PRUNEVIEILLE and François Jean CHERBONNEAU. The shares are held by Françoise SHNEIKER, Emmanuel LEONARD, LUC PRUNEVIEILLE, B2G LIFE SCIENCES, Thomas MUFFAT-JEANDET and Victoire PRUNEVIEILLE. It owns 100% of Quidditas Therapeutics SAS itself.
Directors
According to the 2025 annual accounts
Aurore PRUNEVIEILLE
Director
Is a shareholder
since 2025
François Jean CHERBONNEAU
Administrateur Statutaire
Is a shareholder
Shareholders
Françoise SHNEIKER
Emmanuel LEONARD
LUC PRUNEVIEILLE
B2G LIFE SCIENCES
Thomas MUFFAT-JEANDET
Victoire PRUNEVIEILLE
IXLIFE
Alain BARONNIER
Laurent BRACCO
Aurore PRUNEVIEILLE · director
Thierry MARUCHEAU DE CHANAUD
Renaud Mascarin
Héloïse Mascarin
MIRABELLEBAM
EMPORIO SUN
Anna BONDARENKO
SYGA GROUP
THALEO EUROPE LTD
Marc BATROUNI
Mohamed Raed HERGLI
ETS PRUNEVIEILLE
François Jean CHERBONNEAU · director
Participations
Establishments
Establishment units
Physical locations of this company
Avenue Hippocrate 5
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
XeroThera Europe
€ 196,870 gross margin · 2025
Sagitta Biotech
€ -138,661 gross margin · 2025
ARTIALIS
€ 320,267 gross margin · 2024
Temple OrthoBiologics
€ -225,322 gross margin · 2025
BRENUS PHARMA BELGIUM
+1 more
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
LEVEL27-AS * Please direct all complaints to support@level27.be *, BE
Domain
Domain
spronken.com
Registered
1999-03-31
Registrar
Combell NV
Expires
2026-03-31
Website info
Features
Security
Details
- Company number
- 0794.472.362
- VAT number
- BE 0794.472.362
- Registered office
- Avenue Hippocrate 5, 4000 Liège
- Names & denominations
- QUIDDITAS · QD
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 6 December 2022
- Peppol
- Active · Active since 13 Jun 2025
- Contact
- spronken.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied